Cleveland BioLabs Stock Price, News & Analysis (NASDAQ:CBLI) Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.0003▼$0.000450-Day Range$2.20▼$4.3452-Week Range$1.62▼$10.97Volume28,901 shsAverage Volume271,922 shsMarket Capitalization$6,191.60P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media About Cleveland BioLabs Stock (NASDAQ:CBLI)Cytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.Read More CBLI Stock News HeadlinesSeptember 2, 2023 | usatoday.comEagles' Tyrie Cleveland, Moro Ojomo carted off field after suffering neck injuriesJuly 28, 2023 | bizjournals.comCleveland Construction NewsDecember 10, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comJune 28, 2023 | health.usnews.comBest Hospitals in Cleveland, OHMay 22, 2023 | abcnews.go.comCleveland EMS worker who went missing for 6 days remains hospitalized after found safeMay 17, 2023 | health.usnews.comCleveland Clinic Rehabilitation HospitalApril 19, 2023 | travel.usnews.comGetting Around ClevelandMarch 31, 2023 | thestreet.comCleveland BioLabs Stock Gaps Down On Today's Open (CBLI)December 10, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comMarch 23, 2023 | bizjournals.comCleveland Manufacturing NewsMarch 16, 2023 | bizjournals.comCleveland Commercial Real Estate NewsMarch 12, 2023 | forbes.comCleveland, TNSeptember 9, 2022 | bizjournals.comCleveland NewsAugust 31, 2022 | thestreet.com5 Stocks Under $5 Making Big MovesNovember 15, 2021 | finance.yahoo.comStatera Biopharma Provides Third Quarter 2021 Financial and Corporate UpdateOctober 26, 2021 | finance.yahoo.comCleveland BioLabs Gets Orphan Status for Entolimod in EUSeptember 24, 2021 | reuters.comStatera Biopharma IncSeptember 8, 2021 | finance.yahoo.comWhat is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?September 7, 2021 | finance.yahoo.comStatera BioPharma: The Ticker Formerly Known as CBLISeptember 2, 2021 | seekingalpha.comCytocom to rename as Statera BioPharmaAugust 31, 2021 | finance.yahoo.comCytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."August 18, 2021 | seekingalpha.comCytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call TranscriptAugust 16, 2021 | finance.yahoo.comCytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via WebcastAugust 16, 2021 | finance.yahoo.comCytocom, Inc. Reports Second Quarter 2021 Financial ResultsAugust 12, 2021 | finance.yahoo.comCytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance AgreementAugust 11, 2021 | finance.yahoo.comCytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business ConferenceAugust 10, 2021 | finance.yahoo.comCytocom, Inc. to Report Second Quarter 2021 Financial ResultsSee More Headlines Receive CBLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cleveland BioLabs and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2020Today12/09/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBLI CUSIPN/A CIK1318641 Webwww.cbiolabs.com Phone(888) 613-8802FaxN/AEmployees4Year Founded2003Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,400,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.84% Return on Assets-31.29% Debt Debt-to-Equity RatioN/A Current Ratio45.93 Quick Ratio45.93 Sales & Book Value Annual Sales$260,000.00 Price / Sales0.02 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book0.00Miscellaneous Outstanding Shares15,479,000Free FloatN/AMarket Cap$6,191.60 OptionableNot Optionable Beta0.70 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMichael Kevin HandleyPresident, Chief Executive Officer & DirectorTaunia S. MarkvickaChief Operating Officer & DirectorPeter J. AronstamChief Financial OfficerAndrei V. GudkovGlobal Head-Research & DevelopmentClifford A. SelskyChief Medical OfficerKey CompetitorsNVN LiquidationNASDAQ:NOVNQPhaseBio PharmaceuticalsNASDAQ:PHASStatera BiopharmaNASDAQ:STABGenocea BiosciencesNASDAQ:GNCAQGenocea BiosciencesNASDAQ:GNCAView All Competitors CBLI Stock Analysis - Frequently Asked Questions How were Cleveland BioLabs' earnings last quarter? Cleveland BioLabs, Inc. (NASDAQ:CBLI) released its quarterly earnings data on Friday, May, 15th. The biotechnology company reported ($0.05) EPS for the quarter. The biotechnology company earned $0.16 million during the quarter. What other stocks do shareholders of Cleveland BioLabs own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cleveland BioLabs investors own include Inovio Pharmaceuticals (INO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Biocept (BIOC) and Co-Diagnostics (CODX). This page (NASDAQ:CBLI) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cleveland BioLabs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.